Phentermine: The enduring appetite suppressant that survived the infamous fen-phen era

Phentermine: The enduring appetite suppressant that survived the infamous fen-phen era
Image: Intellect (generated)

In short: Approved in 1959, phentermine remains a widely prescribed obesity treatment despite its chemical kinship with amphetamines. While its former partner, fenfluramine, was pulled from the market in 1997 due to heart valve risks, phentermine persists as a standalone therapy, operating primarily through noradrenergic activation rather than dopaminergic stimulation.

Phentermine, a substituted amphetamine, functions primarily as a norepinephrine and dopamine releasing agent. Unlike many other amphetamines, it is inactive at the vesicular monoamine transporter 2. Research suggests its appetite-suppressant effects are driven more by noradrenergic activation than by dopamine release, which may explain why it is considered a relatively weak reinforcer with negligible addiction risk in humans, despite its stimulant properties.

The drug's history is inextricably linked to the fen-phen combination, which was withdrawn in 1997 after reports of valvular heart disease. Studies revealed that nearly 30% of patients using fenfluramine or dexfenfluramine for up to 24 months developed abnormal valve findings. Crucially, phentermine itself lacks the serotonin-releasing properties and 5-HT2B receptor agonism associated with these cardiac complications, allowing it to remain a legal, Schedule IV controlled substance in the United States.

Pharmacokinetically, phentermine is unique for its minimal metabolism; approximately 62% to 85% of an administered dose is excreted unchanged in the urine. Its elimination half-life is typically 20 to 25 hours, though this can shorten significantly if urine becomes acidic. While it is approved for short-term use of up to 12 weeks, clinical data indicates that weight loss can continue for up to nine months, albeit at a slower rate after the initial weeks.

Modern applications have evolved, including the 2012 FDA approval of Qsymia, a combination of phentermine and topiramate. This development followed years of off-label use by specialists like Thomas Najarian, who began prescribing the combination in 2001. Today, phentermine remains a staple in obesity management, with over 3 million prescriptions recorded in the United States in 2023 alone, underscoring its long-standing role in clinical weight loss strategies.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/science-phentermine.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…